“The US market is critical to our continued success as a global specialty innovator. Today we deliver important therapeutic options to more than 150,000 oncology, multiple sclerosis (MS) and fertility patients in the US,” said Chris Round, president of EMD Serono. “This move serves as an important milestone in our journey to bring further innovation to address high unmet medical needs in areas where patients rely on us. Our vibrant new office setting in the Seaport district will bring EMD Serono into the center of the globally leading healthcare innovation hub to support our future growth,” Round added.

Merck said it plans to introduce one new product or major indication every 1.5 years on average, beginning with two potential US launches in 2025 in three therapeutic areas: neurology and immunology, oncology, and fertility.

The US Healthcare business plans to relocate its headquarters to Boston in summer 2024, maintaining its global research and development hub in Billerica, Massachusetts.